24 September 2026 – 7 October 2026 · published 7 October 2026 · Subscribe
Between 24 September 2026 and 7 October 2026 the tracker indexed 1 new peer-reviewed study and 17 clinical-trial updates across 8 post-viral and post-infectious conditions.
Studies tracked = entries across the 8 condition feeds (each feed keeps a rolling window of recent PubMed results); trials tracked = ClinicalTrials.gov records in the current trial snapshot (last run 2026-10-07); biomarkers catalogued = marker entries across all OSMF biomarker atlases.
Full feed: PACVS research tracker
Severe acute respiratory syndrome (SARS) remains an important cause of hospitalization and mortality, particularly among vulnerable populations. Understanding the factors associated with previous hospitalization may support more effective prevention and vaccination strategies.
No new studies this window for: Long COVID, ME/CFS, Lyme / PTLDS, Gulf War Illness, POTS, MCAS, Other post-viral.
ClinicalTrials.gov records whose registry entry was last updated between 24 September 2026 and 7 October 2026. A registry update can be anything from a status change to an edited contact field; status shown is as of the tracker snapshot.
| NCT | Trial | Status | Phase | Agents | Updated |
|---|---|---|---|---|---|
| NCT07388550 | Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Long COVID | Not Yet Recruiting | Phase 1 | Keytruda | 2026-10-07 |
| NCT05874037 | Fluvoxamine for Long COVID-19 Long COVID | Completed | Phase 2 | Fluvoxamine | 2026-10-07 |
| NCT07661862 | PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID Long COVID | Recruiting | Not applicable | Perceive-Outreach Disease Management Program | 2026-10-06 |
| NCT06928272 | Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study Long COVID | Recruiting | Phase 3 | Pirfenidone, Upadacitinib | 2026-10-06 |
| NCT06404073 | RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM)) Long COVID | Completed | Not applicable | Structured Pacing | 2026-10-06 |
| NCT07398508 | NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Other post-viral | Recruiting | Phase 1 | Droxidopa Oral Product | 2026-10-05 |
| NCT05493605 | Cardiac Involvement in Wilson's Disease Other post-viral | Recruiting | Not applicable | Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope | 2026-10-01 |
| NCT07621588 | Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID Long COVID | Completed | Not applicable | Diaphragmatic Electrostimulation Using Kots Currents, Diaphragmatic Breathing Exercises | 2026-09-29 |
| NCT07468604 | Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition Other post-viral | Recruiting | Phase 4 | 5 Ml Of 0.25% Bupivacaine With Epinephrine | 2026-09-29 |
| NCT07021794 | SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID) Long COVID | Recruiting | Phase 2 | Sipavibart | 2026-09-29 |
| NCT06928116 | Heat thErapy And mobiLity in COVID-19 Survivors Long COVID | Recruiting | Not applicable | Heat Therapy, Walking | 2026-09-28 |
| NCT07842302 | Fighting Fatigue in Multiple Sclerosis: TMS vs. tDCS Efficacy. Other post-viral | Not Yet Recruiting | Not applicable | Tms, Tdcs | 2026-09-25 |
| NCT07005921 | QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG Long COVID | Completed | Not applicable | Qeeg-Neurofeedback | 2026-09-25 |
| NCT06631287 | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID Long COVID | Recruiting | Phase 3 | Baricitinib | 2026-09-25 |
| NCT07837804 | RESET-POTS: Multimodal Phenotyping and Stellate Ganglion Block in Postural Orthostatic Tachycardia Syndrome POTS, Other post-viral | Not Yet Recruiting | Not applicable | Bilateral Sequential Stellate Ganglion Block | 2026-09-24 |
| NCT07123727 | A Study to Examine Anktiva for the Treatment of COVID-19. Long COVID | Recruiting | Phase 2 | Anktiva | 2026-09-24 |
| NCT04137757 | fMRI in Postural Tachycardia Syndrome Other post-viral | Active Not Recruiting | Not applicable | Lower Body Negative Pressure | 2026-09-24 |
Browse all tracked trials: clinical trials tracker.
The same issue goes out by email on Substack. RSS and JSON Feed are available for readers and aggregators.
Subscribe on SubstackRSS feedJSON FeedIssues are regenerated from the live tracker data within their week and frozen afterwards; the snapshot behind this page is at data/2026-W41.json.